AZN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into AstraZeneca (AZN)
AstraZeneca (AZN) shares fell approximately 8.4% in early trading on July 9, 2026, following a Phase III trial failure. SueWallSt notifies investors of a pending investigation into potential claims on behalf of shareholders.
On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint in ATTR cardiomyopathy. If you suffered a loss on your AstraZeneca investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Wainua, a gene-silencing drug for transthyretin-mediated amyloid cardiomyopathy, had been positioned as a key value driver toward AstraZeneca's stated "$80 billion 2030 ambition." The CARDIO-TTransform study was the largest trial in the ATTR cardiomyopathy population. On July 9, 2026, the Company disclosed that the trial did not meet its primary endpoint, and shares declined sharply on the news.
The investigation concerns whether AstraZeneca and certain of its officers may have made materially misleading statements or failed to adequately disclose information regarding the Wainua program prior to the July 9, 2026 announcement. On the Company's Q2 2025 earnings call, held July 29, 2025, management described the CARDIO-TTransform readout as a highly anticipated catalyst for the ATTR cardiomyopathy population.
